drugset

drugset / Trial / NCT03870776

RESIST : Administration of MAP4343 in Antidepressant Non-Responders Patients Experiencing a Major Depressive Episode

NCT03870776 ↗

Phase 2 Completed 126 enrolled Mapreg Eurofins Optimed · collab

RandomizedSequentialQuadruple-blindTreatment

Summary

The study is a phase II, double-blind, randomized, placebo controlled, parallel, multicentric study in 110 patients with drug resistant depression.

Timeline

Start: 2019-06-01
Primary completion: 2024-11-07
Completion: 2024-11-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MAP4343	Unknown	—	Oral

Indications